- FDA allows standalone use of nasal spray antidepressant Spravato (esketamine) : Shots – Health News NPR
- SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression PR Newswire
- FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment CNBC
- Johnson & Johnson’s Spravato gains FDA nod to be used as a monotherapy FiercePharma
- J&J’s ketamine-derived nasal spray approved by FDA to treat depression Fox Business
Discussion about this post